[China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)].

Abstract excerpt

The incidence and mortality of lung cancer rank first among malignant tumors in China. Among them, non-small cell lung cancer (NSCLC) is the most important pathological type, accounting for 80%-85% of lung cancer patients, including adenocarcinoma, squamous cell carcinoma and other pathological subtypes. In recent years, with the discovery of epidermal growth factor receptor (EGFR) gene and the successful...

Topics

Join the communities discussing this publication.

• Amides
• Aniline Compounds
• Carcinoma, Non-Small-Cell Lung
• Indoles
• Propionates
• Protein Kinase Inhibitors